autologous CD40-activated acute lymphoblastic leukemia cell vaccine

The autologous CD40-activated acute lymphoblastic leukemia (ALL) cell vaccine is an investigational cell-based immunotherapy designed for the treatment of B-cell lineage acute lymphoblastic leukemia. The manufacturing process involves harvesting a patient's own (autologous) leukemia cells and activating them ex vivo through the CD40 signaling pathway, typically by exposure to CD40 ligand (CD40L/CD154). This activation induces a phenotypic shift in the B-ALL cells, which are normally poorly immunogenic, transforming them into professional antigen-presenting cells (APCs). This transformation is characterized by the significant upregulation of MHC class I and II molecules, as well as costimulatory molecules such as CD80 and CD86. Upon re-administration to the patient, these modified cells present a broad spectrum of leukemia-associated antigens to the host immune system, thereby stimulating a potent, systemic cytotoxic T-lymphocyte (CTL) response intended to eradicate minimal residual disease and prevent leukemic relapse.

Other names

CD40L-activated autologous B-ALL cell vaccineCD-40L-activated autologous B-ALL cell vaccineCD 40L-activated autologous B-ALL cell vaccineautologous CD40L-activated B-ALL cellsautologous CD154-activated B-ALL cell vaccine